Theravance Biopharma, Inc. Net Cash Provided by (Used in) Continuing Operations
Theravance Biopharma, Inc. (TBPH) reported Net Cash Provided by (Used in) Continuing Operations of -$174.76 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2017-05-10
- Theravance Biopharma, Inc. net cash provided by (used in) continuing operations for the quarter ending 2017-03-31 was -$174.76M, a 1185.76% decline year-over-year.
- Theravance Biopharma, Inc. net cash provided by (used in) continuing operations for the quarter ending 2016-12-31 was $258.14M.
- Theravance Biopharma, Inc. net cash provided by (used in) continuing operations for the quarter ending 2016-09-30 was -$61.79M, a 305.81% decline year-over-year.
- Theravance Biopharma, Inc. net cash provided by (used in) continuing operations for the quarter ending 2016-06-30 was $19.56M.
- Theravance Biopharma, Inc. net cash provided by (used in) continuing operations for fiscal 2016 was $232.00M, a 887.58% increase from fiscal 2015.
- Theravance Biopharma, Inc. net cash provided by (used in) continuing operations for fiscal 2015 was $23.49M, a 73.67% decline from fiscal 2014.
- Theravance Biopharma, Inc. net cash provided by (used in) continuing operations for fiscal 2014 was $89.22M.
- Theravance Biopharma, Inc. net cash provided by (used in) continuing operations for fiscal 2013 was $0.00.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | -$174.76M 10-Q · filed 2017-05-10 | $83.37M derived: sum of 2 quarters · filed 2017-05-10 | $21.58M derived: sum of 3 quarters · filed 2017-05-10 | $41.14M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | $258.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $196.35M derived: sum of 2 quarters · filed 2017-03-01 | $215.91M derived: sum of 3 quarters · filed 2017-03-01 | $232.00M 10-K · filed 2017-03-01 |
| 2016-09-30 | -$61.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$42.23M derived: sum of 2 quarters · filed 2016-11-09 | -$26.14M 10-Q · filed 2016-11-09 | -$40.54M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-06-30 | $19.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $35.66M 10-Q · filed 2016-08-09 | $21.25M derived: sum of 3 quarters · filed 2017-05-10 | $51.27M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-03-31 | $16.10M 10-Q · filed 2017-05-10 | $1.69M derived: sum of 2 quarters · filed 2017-05-10 | $31.71M derived: sum of 3 quarters · filed 2017-05-10 | $27.90M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $15.62M derived: sum of 2 quarters · filed 2017-03-01 | $11.81M derived: sum of 3 quarters · filed 2017-03-01 | $23.49M 10-K · filed 2017-03-01 |
| 2015-09-30 | $30.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $26.21M derived: sum of 2 quarters · filed 2016-11-09 | $37.90M 10-Q · filed 2016-11-09 | $4.89M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$3.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $7.88M 10-Q · filed 2016-08-09 | -$25.14M derived: sum of 3 quarters · filed 2017-03-01 | -$171.11M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $11.68M 10-Q · filed 2016-05-10 | -$21.33M derived: sum of 2 quarters · filed 2017-03-01 | -$167.30M derived: sum of 3 quarters · filed 2017-03-01 | $100.90M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$33.01M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$178.98M derived: sum of 2 quarters · filed 2017-03-01 | $89.22M derived: sum of 3 quarters · filed 2017-03-01 | $89.22M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$145.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $122.23M derived: sum of 2 quarters · filed 2015-11-12 | $122.23M 10-Q · filed 2015-11-12 | $122.23M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $268.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $268.20M 10-Q · filed 2015-08-13 | $268.20M derived: sum of 3 quarters · filed 2016-03-11 | $268.20M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-13 | $0.00 derived: sum of 2 quarters · filed 2016-03-11 | $0.00 derived: sum of 3 quarters · filed 2016-03-11 | $0.00 derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $0.00 derived: sum of 2 quarters · filed 2016-03-11 | $0.00 derived: sum of 3 quarters · filed 2016-03-11 | $0.00 10-K · filed 2016-03-11 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $0.00 derived: sum of 2 quarters · filed 2014-11-12 | $0.00 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |